Expand VIR Menu
VIR MENU

VIR Latest Press Releases

-- April 23, 2026 --

Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results Business Wire 4:05 PM

-- April 16, 2026 --

Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer Business Wire 8:05 AM

-- April 13, 2026 --

Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Business Wire 8:05 AM

-- February 26, 2026 --

Vir Biotechnology to Participate in Upcoming Investor Conferences Business Wire 4:05 PM

-- February 25, 2026 --

Vir Biotechnology Announces Pricing of Public Offering of Common Stock Business Wire 10:31 PM

-- February 24, 2026 --

Vir Biotechnology Announces Proposed Public Offering of Common Stock Business Wire 4:05 PM
Biotech and Big Tech Drive the Morning Narrative Globe Newswire 10:17 AM

-- February 23, 2026 --

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results Business Wire 5:14 PM
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer Business Wire 5:02 PM
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer PRNewswire 5:00 PM

-- February 9, 2026 --

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results Business Wire 4:05 PM

-- January 12, 2026 --

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones Business Wire 8:00 AM

-- January 5, 2026 --

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference Business Wire 4:05 PM

-- December 16, 2025 --

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program Business Wire 4:05 PM
Market Data Delayed 15 Minutes